ClinicalTrials.gg
CompletedNCT05256732Updated Oct 18, 2022

Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal

A Phase 1 interventional study of AT-527 fasted and Placebo Comparator fasted in Healthy Volunteer Study, sponsored by Atea Pharmaceuticals, Inc.. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 following oral administration under fasting conditions or with a meal in healthy adult subjects

02

Conditions studied

  • Healthy Volunteer Study
03

In context

Lead sponsor

Atea Pharmaceuticals, Inc. is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 4 (16%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must agree to use two methods of from Screening through 90 days after administration of the last dose of study drug
  • Females must have a negative pregnancy test at Screening and prior to dosing
  • Minimum body weight of 50 kg and (BMI) of 18-32 kg/m2
  • Willing to comply with the study requirements and to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Infected with virus, virus, or COVID-19
  • Abuse of alcohol or drugs
  • Use of other drugs within 28 days of dosing
  • Other medical conditions or laboratory abnormalities
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    AT-527

    Drug: AT-527 fasted · Drug: AT-527 fed

  • Placebo comparator
    Placebo

    Other: Placebo Comparator fasted · Other: Placebo Comparator fed

  • Experimental
    AT-527 BID

    Drug: AT-527

  • Experimental
    AT-527 single dose fasted/fed

    Drug: AT-527 single dose

Interventions

  • AT-527 administered twice daily (BID) for 5 days fasted

    Also known as: Bemnifosbuvir

  • OtherPlacebo Comparator fasted

    Matching placebo administered twice daily (BID) for 5 days fasted

  • AT-527 administered twice daily (BID) for 5 days fed

    Also known as: Bemnifosbuvir

  • OtherPlacebo Comparator fed

    Matching placebo administered twice daily (BID) for 5 days fed

  • DrugAT-527

    AT-527 administered twice daily (BID)

    Also known as: Bemnifosbuvir

  • AT-527 single dose fasted/fed cross-over

    Also known as: Bemnifosbuvir

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of AT-527

    Maximum plasma concentration (Cmax)

    Time frame: Day 1

  2. Pharmacokinetics (PK) of AT-527

    Area under the concentration-time curve (AUC)

    Time frame: Day 1

  3. Pharmacokinetics (PK) of AT-527

    Trough plasma concentration (Ctrough)

    Time frame: Day 1

  4. Proportions of subjects experiencing treatment-emergent adverse events

    Time frame: Day 1-10

07

Study locations

1 site
  • Atea Study Site
    Québec, Montreal, Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Aug 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Feb 25, 2022
StartActual
Feb 22, 2022
Primary completionActual
Aug 23, 2022
CompletionActual
Aug 23, 2022
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05256732
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Feb 22, 2022
Primary completion
Aug 23, 2022
Completion
Aug 23, 2022
Last update
Oct 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bemnifosbuvir

Start the discussion